The UK's GlaxoSmithKline is expected to openly challenge its competitors in oncology with a lineup of 34 data presentations at the upcoming meeting of the American Society of Clinical Oncology in Atlanta. Tykerb, the subject of 13 of those planned presentations, and Cervarix are both slated to go on the market next year. GSK clearly sees the Atlanta session as a staging ground of sorts for claiming a bigger share of the market for cancer drugs. Cancer is one of the fastest growing drug markets and has offered some of the greatest profit margins.
- read the release [1] with GSK's lineup of presentations
Links:
[1] http://www.pharmalive.com/News/index.cfm?articleid=343774&categoryid=63